Skip to main content

MYD88 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon1 and 1 bp insertion in exon1 and 2 bp deletion in exon1.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human MYD88 knockout A549 cell lysate (AB256997), expandable thumbnail
  • Sanger Sequencing - Human MYD88 knockout A549 cell lysate (AB256997), expandable thumbnail
  • Sanger Sequencing - Human MYD88 knockout A549 cell lysate (AB256997), expandable thumbnail

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon1 and 1 bp insertion in exon1 and 2 bp deletion in exon1.

Alternative names

What's included?

1 Kit
Components
Human MYD88 knockout A549 cell lysate
1 x 100 µg
Human wild-type A549 cell lysate
1 x 100 µg

Recommended products

MYD88 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon1 and 1 bp insertion in exon1 and 2 bp deletion in exon1.

Key facts

Cell type

A549

Mutation description

Knockout achieved by using CRISPR/Cas9, 13 bp deletion in exon1 and 1 bp insertion in exon1 and 2 bp deletion in exon1.

Disease

Carcinoma

Concentration
Loading...

Properties

Gene name

MYD88

Gene editing type

Knockout

Gene editing method

CRISPR technology

Knockout validation

Sanger Sequencing

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension
Adherent
Gender

Male

Storage

Shipped at conditions

Ambient - Can Ship with Ice

Appropriate short-term storage conditions

-20°C

Appropriate long-term storage conditions

-20°C

Notes

Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

MyD88 standing for myeloid differentiation primary response 88 is a cytoplasmic adaptor protein with a molecular weight of approximately 33 kDa. This protein is expressed widely in immune cells including monocytes macrophages and dendritic cells. MyD88 serves a major role in the signaling pathways for the innate immune system. It acts as a linker transmitting signals from toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) to downstream signaling molecules ultimately activating transcription factors.

Biological function summary

MyD88 plays a significant role in mediating immune responses by forming part of a complex that includes IRAK kinases and TRAF6. When TLRs or IL-1Rs activate MyD88 this adaptor protein recruits IRAK4 which then phosphorylates IRAK1 or IRAK2. This cascade promotes the activation of NF-κB and MAPK pathways leading to the production of inflammatory cytokines. The MyD88-dependent pathway is integral to innate immunity influencing how the body responds to pathogen infection and inflammation.

Pathways

MyD88 integrates into both the TLR signaling and IL-1R signaling pathways. Key related proteins in these pathways include interleukin-1 receptor-associated kinase (IRAK) and tumor necrosis factor receptor-associated factor 6 (TRAF6). MyD88 initiates the recruitment and activation of IRAK1 and IRAK4 following receptor engagement leading to subsequent activation of downstream signals. As part of these pathways MyD88 mediates cellular responses important for immune system signaling and inflammatory response regulation.

Associated diseases and disorders

MyD88 involvement is notable in the context of oncological and autoimmune diseases. Mutations or dysregulation of MyD88 are implicated in conditions like lymphoma and rheumatoid arthritis. In lymphoma the mutation usually results in constant activation of NF-κB leading to unchecked cell growth. As for rheumatoid arthritis an overactive immune response due to MyD88 can cause additional inflammation affecting joint tissues. In these conditions MyD88 interaction with IRAK4 is significant given their mutual role in immune and inflammatory pathways.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997), expandable thumbnail

    Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997)

    Allele-3: 1 bp insertion in exon1

  • Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997), expandable thumbnail

    Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997)

    Allele-2: 2 bp deletion in exon1

  • Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997), expandable thumbnail

    Sanger Sequencing - Human MYD88 knockout A549 cell lysate (ab256997)

    Allele-1: 13 bp deletion in exon1

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com